BioArctic AB (OSTO:BIOA B)
kr 238.4 5 (2.14%) Market Cap: 21.06 Bil Enterprise Value: 20.57 Bil PE Ratio: 0 PB Ratio: 21.21 GF Score: 55/100

Q3 2023 BioArctic AB Earnings Call Transcript

Nov 08, 2023 / 08:30AM GMT
Release Date Price: kr213 (-1.75%)
Operator

This call is being recorded. Welcome to the BioArctic Q3 presentation for 2023. (Operator Instructions) Now I will hand the conference over to the CEO, Gunilla Osswald; and CFO, Anders Martin-Lof. Please go ahead.

Gunilla Osswald;publ;CEO
BioArctic AB

()-

Good morning, and welcome to BioArctic's presentation for the third quarter of 2023. I'm Gunilla Osswald and I'm the CEO of BioArctic and I will share today's presentation with our CFO, Anders Martin-Lof. I think it's very exciting times for BioArctic with LEQEMBI being the first and only disease-modifying treatment with a full approval in the U.S. and now also in Japan. And both these things happened during this quarter. I think it's beginning of a new era. And BioArctic is behind this true breakthrough in the treatment of Alzheimer's disease. I find this extremely gratifying that we now can help a large number of patients and families around the world. And I'll talk more about that here today.

Next slide, please. BioArctic is listed at Nasdaq Stockholm Large Cap and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot